Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2025
Esperion partner HLS Therapeutics announces approval of Nilemdo for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease
18 November 2025 - Esperion today announced that HLS Therapeutics, the Company’s partner in Canada for the development and commercialization ...
Posted by Michael Wonder on 18 Nov 2025
Lupron Depot new strength receives Health Canada approval for the treatment of advanced prostate cancer
17 November 2025 - AbbVie announced today that a new 6 month 45 mg Lupron Depot (leuprolide acetate for extended release ...
Posted by Michael Wonder on 14 Nov 2025
Arcutis Canada announces Health Canada approval of Zorvye 0.3% topical foam, the first steroid-free topical foam for scalp and body psoriasis, for adults and adolescents ages 12 and older
13 November 2025 - Approval supported by pivotal Phase 3 and Phase 2 data demonstrating rapid improvement in skin clearance and ...
Posted by Michael Wonder on 13 Nov 2025
Marius Pharmaceuticals expands global footprint with Health Canada approval of Kyzatrex (testosterone undecanoate) CIII capsules
12 November 2025 - Marius Pharmaceuticals today announced that Health Canada has approved Kyzatrex (testosterone undecanoate) CIII capsules. ...
Posted by Michael Wonder on 06 Nov 2025
argenx announces Vvygart SC pre-filled syringe for self-Injection in chronic inflammatory demyelinating polyneuropathy authorised for sale by Health Canada
5 November 2025 - argenx today announced that Health Canada has issued a Notice of Compliance authorising Vvyvart SC (efgartigimod alfa ...
Posted by Michael Wonder on 31 Oct 2025
Enhertu approved in Canada as the first and only HER2 directed therapy for patients with HR positive HER2 low or HER2 ultra low metastatic breast cancer, following disease progression after one or more endocrine therapies
29 October 2025 - Based on the DESTINY-Breast06 Phase 3 trial results demonstrating statistically significant and clinically meaningful progression-free survival ...
Posted by Michael Wonder on 27 Oct 2025
Health Canada grants authorisation for Leqembi (lecanemab) for the treatment of early Alzheimer’s disease
26 October 2025 - Eisai and Biogen announced today that Health Canada has issued a notice of compliance with conditions for ...
Posted by Michael Wonder on 24 Oct 2025
Biocon Biologics receives Health Canada spproval for Yesintek and Yesintek I.V. (ustekinumab), a biosimilar to Stelara
23 October 2025 - Biocon Biologics today announced that Health Canada has granted a notice of compliance for Yesintek (ustekinumab ...
Posted by Michael Wonder on 24 Oct 2025
Apotex receives Health Canada approval for Loqtorzi - the first and only immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer
23 October 2025 - Apotex today announced that Health Canada has granted a notice of compliance for Loqtorzi (toripalimab) for ...
Posted by Michael Wonder on 23 Oct 2025
Dupixent (dupilumab injection) approved in Canada for adults with inadequately controlled chronic obstructive pulmonary disease
22 October 2025 - Health Canada has approved Dupixent (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...
Posted by Michael Wonder on 22 Oct 2025
Lyvdelzi (seladelpar) receives Health Canada approval for the treatment of primary biliary cholangitis
21 October 2025 - Gilead Sciences today announced that Health Canada has approved Lyvdelzi (seladelpar) for the treatment of primary biliary ...
Posted by Michael Wonder on 22 Oct 2025
Pfizer Canada announces Health Canada approval of Abrysvo for adults 18+
21 October 2025 - With the approval of Arbysvo for adults aged 18+, there is now a way to help ...
Posted by Michael Wonder on 16 Oct 2025
Incyte Canada announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis in children ages 2-11
15 October 2025 - First and only topical JAK inhibitor cream approved in Canada for paediatric atopic dermatitis. ...
Posted by Michael Wonder on 07 Oct 2025
Jesse's dad, who walked Canada for his son, cheers approval of new Duchenne drug
3 October 2025 - Vamorolone is the first Health Canada approved drug developed specifically to treat Duchenne. ...
Posted by Michael Wonder on 03 Oct 2025
Health Canada approves Agamree (vamorolone) as the first treatment for Duchenne muscular dystrophy in Canada
2 October 2025 - Kye Pharmaceuticals announced today that Health Canada has approved Agamree (vamorolone) for the treatment of Duchenne muscular ...